Section Arrow
DTIL.NASDAQ
- Precision BioSciences
Quotes are at least 15-min delayed:2026/08/01 22:07 EDT
Regular Hours
Last
 6.99
-0.01 (-0.14%)
Day High 
7.21 
Prev. Close
1-M High
9.62 
Volume 
211.11K 
Bid
6.66
Ask
8
Day Low
6.76 
Open
7.08 
1-M Low
6.7 
Market Cap 
180.62M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 7.31 
20-SMA 8.01 
50-SMA 7.33 
52-W High 9.62 
52-W Low 3.53 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.10/-1.74
Enterprise Value
207.92M
Balance Sheet
Book Value Per Share
3.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
34.26M
Operating Revenue Per Share
2.03
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
REPLReplimune Group11.2+5.79+107.02%-- 
GOSSGossamer Bio0.1695-0.0088-4.94%-- 
JUNSJupiter Neurosciences Inc0.09-0.0075-7.69%-- 
KPTIKaryopharm Therapeutics Inc.1.92-5.09-72.61%-- 
IOVAIovance Biotherapeutics4.07-0.62-13.22%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.